Sanctuary Advisors LLC Reduces Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Sanctuary Advisors LLC lowered its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 6.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 34,486 shares of the biopharmaceutical company’s stock after selling 2,553 shares during the quarter. Sanctuary Advisors LLC’s holdings in Halozyme Therapeutics were worth $1,649,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in HALO. Geode Capital Management LLC raised its stake in shares of Halozyme Therapeutics by 1.0% in the third quarter. Geode Capital Management LLC now owns 3,060,131 shares of the biopharmaceutical company’s stock worth $175,194,000 after purchasing an additional 30,901 shares during the last quarter. Congress Asset Management Co. raised its position in Halozyme Therapeutics by 446.5% during the 3rd quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock worth $139,298,000 after buying an additional 1,988,238 shares during the last quarter. Boston Trust Walden Corp lifted its stake in Halozyme Therapeutics by 28.0% during the 4th quarter. Boston Trust Walden Corp now owns 874,081 shares of the biopharmaceutical company’s stock valued at $41,790,000 after acquiring an additional 191,465 shares during the period. Janus Henderson Group PLC lifted its stake in Halozyme Therapeutics by 6.2% during the 3rd quarter. Janus Henderson Group PLC now owns 545,173 shares of the biopharmaceutical company’s stock valued at $31,204,000 after acquiring an additional 31,871 shares during the period. Finally, Glenmede Trust Co. NA boosted its holdings in shares of Halozyme Therapeutics by 28.9% in the 3rd quarter. Glenmede Trust Co. NA now owns 487,131 shares of the biopharmaceutical company’s stock valued at $27,883,000 after acquiring an additional 109,283 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insider Activity at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the completion of the sale, the director now directly owns 43,611 shares in the company, valued at approximately $2,180,986.11. The trade was a 18.65 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.40% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Trading Up 1.3 %

Shares of NASDAQ:HALO opened at $58.50 on Tuesday. The business’s 50 day moving average price is $53.67 and its 200-day moving average price is $54.67. Halozyme Therapeutics, Inc. has a 1 year low of $37.73 and a 1 year high of $65.53. The firm has a market capitalization of $7.20 billion, a price-to-earnings ratio of 17.06, a price-to-earnings-growth ratio of 0.42 and a beta of 1.25. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The company had revenue of $298.01 million during the quarter, compared to analysts’ expectations of $285.74 million. On average, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HALO has been the subject of several recent research reports. HC Wainwright raised their target price on shares of Halozyme Therapeutics from $70.00 to $72.00 and gave the stock a “buy” rating in a report on Wednesday, February 19th. Wells Fargo & Company reduced their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. JMP Securities upped their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. Benchmark reiterated a “buy” rating and set a $75.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Finally, Piper Sandler boosted their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $62.78.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.